Article
Oncology
Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Carly Leventoff, Timothy White, Catherine A. Flynn, Shayna Sarosiek, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Andrew R. Branagan, Elizabeth O'Donnell, Noopur Raje, Andrew J. Yee, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon
Summary: Ibrutinib monotherapy showed durable responses in treatment-naive patients with Waldenstrom macroglobulinemia, with CXCR4 mutations impacting VGPR attainment, time to major response, and 4-year PFS rate.
Article
Oncology
Steven P. Treon, Kirsten Meid, Joshua Gustine, Guang Yang, Lian Xu, Xia Liu, Christopher J. Patterson, Zachary R. Hunter, Andrew R. Branagan, Jacob P. Laubach, Irene M. Ghobrial, M. Lia Palomba, Ranjana Advani, Jorge J. Castillo
Summary: In this study, the long-term and final analysis of ibrutinib monotherapy in previously treated patients with WM showed promising results in disease control. Response to treatment was impacted by mutation status of MYD88 and CXCR4, with MYD88(Mut)CXCR4(WT) patients demonstrating higher progression-free survival rates. Treatment with ibrutinib was well-tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Cecile Tomowiak, Stephanie Poulain, Charles Herbaux, Aurore Perrot, Beatrice Mahe, Pierre Morel, Therese Aurran, Olivier Tournilhac, Stephane Lepretre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Veronique Leblond
Summary: The combination of idelalisib + obinutuzumab was effective in treating R/R WM, with high overall response rate and major response rate. Genetic factors, specifically CXCR4 genotypes, did not significantly impact treatment outcomes, but TP53 mutations were associated with poorer survival. However, some patients discontinued the study due to side effects.
Article
Hematology
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo
Summary: Continuation of ibrutinib until subsequent treatment is associated with improved disease control and clinical outcomes in patients with acquired resistance to ibrutinib monotherapy for Waldenstrom macroglobulinemia.
Article
Hematology
Jithma P. Abeykoon, Saurabh Zanwar, Stephen M. Ansell, Eli Muchtar, Rong He, Patricia T. Greipp, Rebecca L. King, Sikander Ailawadhi, Jonas Paludo, Jeremy T. Larsen, Thomas M. Habermann, David Inwards, Ronald S. Go, Gita Thanarajasingam, Francis Buadi, Angela Dispenzieri, Carrie A. Thompson, Thomas E. Witzig, Martha Lacy, Wilson Gonsalves, Grzegorz S. Nowakowski, David Dingli, Sundararajan Vincent Rajkumar, Robert A. Kyle, Taimur Sher, Vivek Roy, Allison Rosenthal, Asher A. Chanan-Khan, Craig Reeder, Morie A. Gertz, Shaji Kumar, Prashant Kapoor
Summary: The study found that the R-Benda regimen showed superior overall response rate, progression-free survival, and time-to-next therapy in treatment-naive patients with active WM compared to DRC and BDR regimens. Overall survival was similar across the three cohorts. The MYD88(L265P) mutation status did not impact patient outcomes with any of the three regimens.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Steven P. Treon, Kirsten Meid, Zachary R. Hunter, Catherine A. Flynn, Shayna R. Sarosiek, Carly R. Leventoff, Timothy P. White, Yang Cao, Aldo M. Roccaro, Antonio Sacco, Maria G. Demos, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Lian Xu, Christopher J. Patterson, Manit Munshi, Nicholas Tsakmaklis, Guang Yang, Irene M. Ghobrial, Andrew R. Branagan, Jorge J. Castillo
Summary: The study examined the combination of CXCR4-antagonist ulocuplumab and ibrutinib in treating WM patients, demonstrating promising clinical efficacy and survival outcomes.
Article
Hematology
Shayna Sarosiek, Joshua N. N. Gustine, Catherine A. A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. P. Treon, Jorge J. J. Castillo
Summary: Waldenstrom macroglobulinaemia (WM) is a type of blood cancer with a specific mutation known as MYD88(L265P). This mutation activates the Bruton tyrosine kinase (BTK), promoting the growth and survival of malignant cells. Ibrutinib is a BTK inhibitor approved for the treatment of WM. However, the impact of reducing the dosage of ibrutinib has not been extensively studied.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Jorge J. Castillo, John N. Allan, Tanya Siddiqi, Ranjana H. Advani, Kirsten Meid, Carly Leventoff, Timothy P. White, Catherine A. Flynn, Shayna Sarosiek, Andrew R. Branagan, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Christopher J. Patterson, Zachary R. Hunter, Matthew S. Davids, Richard R. Furman, Steven P. Treon
Summary: Venetoclax demonstrates safety and efficacy in previously treated WM patients, including those who previously received BTKis. CXCR4 mutation status does not affect treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Jorge J. Castillo, Shayna R. Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Timothy P. White, Kirsten Meid, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Andrew R. Branagan, Steven P. Treon
Summary: This study confirms the predictive and prognostic value of CXCR4 mutations in patients with Waldenstroeurom macroglobulinemia (WM) treated with ibrutinib monotherapy.
Article
Hematology
Maria Poza, Rodrigo Iniguez, Irene Zamanillo, Sara Redondo, Rafael Alonso, Joaquin Martinez-Lopez, Ana Jimenez-Ubieto
Summary: In Waldenstrom macroglobulinemia patients with acquired von Willebrand syndrome, treatment with ibrutinib may lead to a rapid increase in von Willebrand factor levels, improving bleeding symptoms despite only achieving partial response in IgM levels. This improvement could be attributed to reduced glycoprotein Ib receptor expression induced by ibrutinib and subsequent increase in von Willebrand factor levels in the blood.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Shayna Sarosiek, Steven P. Treon, Jorge J. Castillo
Summary: The treatment of WM can lead to a variety of adverse events, including myeloid neoplasms, IgM flares, infusion reactions, neuropathy, bleeding, and cardiac arrhythmias. Clinicians can use dose reductions, lower cycles, and changes in route of administration to manage and minimize toxicity while future research focuses on improving patient safety.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Oncology
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V. Matous, David MacDonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango-Hisijara, Meletios A. Dimopoulos
Summary: The study demonstrates that single-agent ibrutinib continues to show sustained efficacy and tolerability in patients with heavily pretreated, rituximab-refractory Waldenstrom macroglobulinemia. The response rates deepened over time during the long-term treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Hematology
Emanuele Cencini, Ilaria Romano, Francesco Ghio, Chiara Camerini, Ilaria Bertaggia, Roberta Giachetti, Lara Mannelli, Maria Teresa Pirrotta, Giulia Lucco Navei, Manuel Ciceri, Giulia Cervetti, Emanuela Sant'Antonio, Federico Simonetti, Silvia Birtolo, Benedetta Puccini, Monica Bocchia, Alberto Fabbri
Summary: This study retrospectively analyzed 49 consecutive R/R WM patients treated with ibrutinib, the overall response rate reached 91.8%. The 2-year progression-free survival rate was 76.7%, and the duration of response was sustained. Treatment toxicity was common but manageable in most cases without discontinuation.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Ansel Nalin, Qiuhong Zhao, Timothy Voorhees, David Bond, Yazeed Sawalha, Walter Hanel, Audrey Sigmund, Kaitlin Annunzio, Lapo Alinari, Robert Baiocchi, Kami Maddocks, Dan Jones, Beth Christian, Narendranath Epperla
Summary: This study evaluated the prognostic relevance of circulating lymphoma (CL) in patients with Waldenstrom macroglobulinemia (WM). The results showed that CL did not have a predictive effect on outcomes in newly diagnosed WM patients. Future studies should explore the correlation between CL and other biological factors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Karan L. Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L. King, Rong He, Wilson Gonsalves, David Inwards, Thomas E. Witzig, Abhisek Swaika, Tania Jain, Nelson Leung, Sikander Ailawadhi, Craig B. Reeder, Martha Q. Lacy, S. Vincent Rajkumar, Shaji Kumar, Robert A. Kyle, Morie A. Gertz, Stephen M. Ansell, Prashant Kapoor
Summary: Waldenstrom macroglobulinemia (WM) is a rare, indolent lymphoma that mostly affects the elderly. A study compared young WM patients to their older counterparts and found that young patients have lower overall survival and higher death attributable to WM. The treatment strategies for WM have not improved the outcome of young patients, and the impact of Bruton tyrosine kinase inhibitors on this patient population is still unknown.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Dermatology
Ronald Mendoza, M. Pilar Quinones, Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Celia Moises, Gadwyn Sanchez, Jorge J. Castillo, Carlos Torres-Cabala
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Hematology
Shayna Sarosiek, Joshua N. N. Gustine, Catherine A. A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. P. Treon, Jorge J. J. Castillo
Summary: Waldenstrom macroglobulinaemia (WM) is a type of blood cancer with a specific mutation known as MYD88(L265P). This mutation activates the Bruton tyrosine kinase (BTK), promoting the growth and survival of malignant cells. Ibrutinib is a BTK inhibitor approved for the treatment of WM. However, the impact of reducing the dosage of ibrutinib has not been extensively studied.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Danka Cholujova, Gabor Beke, Zachary R. Hunter, Teru Hideshima, Ludmila Flores, Tatiana Zeleznikova, Denisa Harrachova, Lubos Klucar, Merav Leiba, Lubos Drgona, Steven P. Treon, Efstathios Kastritis, David M. Dorfman, Kenneth C. Anderson, Jana Jakubikova
Summary: By using mass cytometry, this study characterized the immunophenotypic changes in Waldenstrom macroglobulinemia (WM) and revealed the modulation of immune cells by immune checkpoints. It was found that the response to treatment strategies in WM can be monitored by observing the changes in immune cells.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Denisse Castro, Bryan Valcarcel, Thanya Runciman, Yesenia Huerta-Collado, Sally Paredes, Brady E. Beltran, Jorge J. Castillo, Luis Malpica
Summary: We evaluated the effect of high red distribution width-coefficient of variation (RDW-CV) values (>14%) on all-cause and lymphoma-specific mortality outcomes among 118 patients with peripheral T-cell lymphoma (PTCL). Results showed that patients with a high RDW-CV had a lower overall survival rate and a higher cumulative incidence of lymphoma mortality. RDW-CV emerges as an easily accessible and complementary prognostic biomarker for risk stratification among treated patients with de novo PTCL.
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Steven P. Treona, Alessandra Tedeschi, Jesus San-Miguel, Ramon Garcia-Sanz, Kenneth C. Anderson, Eva Kimby, Monique C. Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S. Tam, Jorge J. Castillo, Pierre Morel, Meletios Dimopoulos, Roger G. Owen
Summary: The consensus panel reviewed the current criteria for diagnosis and response assessment of Waldenstrom's Macroglobulinemia. The key recommendations included reaffirming the previous consensus panel's recommendation to not use arbitrary values for laboratory parameters to distinguish between Waldenstrom's Macroglobulinemia and IgM MGUS, delineating IgM MGUS into two subclasses, and recognizing simplified response assessments using serum IgM levels.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
Christian Buskea, Jorge J. Castillo, Jithma Prasad Abeykoonc, Ranjana Advanid, Suzanne O. Arulogune, Andrew R. Branaganf, Xinxin Caog, Shirley D'Sae, Jian Houh, Prashant Kapoorc, Efstathios Kastritisi, Marie J. Kerstenj, Veronique LeBlondk, Merav Leibal, Jeffrey V. Matous, Jonas Paludo, Lugui Qiu, Constantine S. Tam, Alessandra Tedeschi, Sheeba K. Thomas, Ibrahim Tohidi-Esfahani, Marzia Varettonis, Josephine M. Vosj, Ramon Garcia-Sanz, Jesus San-Miguel, Meletios A. Dimopoulos, Steven P. Treon, Judith Trotmanr
Summary: The consensus panel recommends watchful waiting for asymptomatic patients, and chemoimmunotherapy (CIT) regimens or covalent BTK inhibitors (cBTKi) for first-line treatment of symptomatic patients. The mutational status of MYD88 and CXCR4 should be determined before treatment initiation. Treatment approaches for WM-associated complications aim to reduce tumor burden and abnormal protein levels. Patients' participation in clinical trials is crucial for the continuous improvement of treatment options.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
S. D'Sa, J. Matous, R. Advani, C. Buske, J. J. Castillo, M. Gatt, P. Kapoor, M. J. Kersten, V Leblond, M. Leiba, M. L. Palomba, J. Paludo, L. Qiu, S. Sarosiek, M. Shadman, D. Talaulikar, C. S. Tam, A. Tedeschi, S. K. Thomas, I Tohidi-Esfahani, J. Trotman, M. Varettoni, J. M. Vos, R. Garcia-Sanz, J. San-Miguel, M. A. Dimopoulos, S. P. Treon, E. Kastritis
Summary: The consensus panel 2 (CP2) of the 11th International Workshop on Waldenstrom's macroglobulinemia (IWWM-11) updated the recommendations for treating patients with relapsed or refractory WM (RRWM) based on current data. The key recommendations include considering chemoimmunotherapy and/or covalent Bruton tyrosine kinase strategies, taking into account patient characteristics, disease phenotype, mutational status, and toxicities. After BTKi failure, various treatment options such as different CIT regimens, addition of anti-CD20 antibody, and newer BTKi or non-covalent BTKi can be considered. Participation in clinical trials should be encouraged.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
C. S. Tam, P. Kapoor, J. J. Castillo, C. Buske, S. M. Ansell, A. R. Branagan, E. Kimby, Y. Li, M. L. Palomba, L. Qiu, M. Shadman, J. P. Abeykoon, S. Sarosiek, J. M. Vos, S. Yi, D. Stephens, D. Roos-Weil, A. M. Roccaro, P. Morel, N. C. Munshi, K. C. Anderson, J. San-Miguel, R. Garcia-Sanz, M. A. Dimopoulos, S. P. Treon, M. J. Kersten
Summary: Recent advances in understanding WM biology have influenced the development of novel agents and improved knowledge of WM genomics. CP7 examined completed and ongoing clinical trials and made recommendations for future trials, prioritizing limited duration and novel agent combinations. Evaluating MYD88, CXCR4, and TP53 at baseline and using bendamustine-rituximab or dexamethasone, rituximab and cyclophosphamide as standard treatments were suggested. Unanswered questions include defining frailty, determining the importance of achieving VGPR within a specific time frame, and providing optimal treatment for WM populations with special needs.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
Ramon Garcia-Sanz, Marzia Varettoni, Cristina Jimenez, Simone Ferrero, Stephanie Poulain, Jesus F. San-Miguel, Maria L. Guerrera, Daniela Drandi, Tina Bagratuni, Mary McMaster, Aldo M. Roccaro, Damien Roos-Weil, Merav Leiba, Yong Li, Luigi Qiu, Jian Hou, C. Fernandez De Larrea, Jorge J. Castillo, M. Dimopoulos, R. G. Owen, S. P. Treon, Z. R. Hunter
Summary: In addition to the MYD88L265P mutation, there is extensive information on the molecular mechanisms in Waldenstrom's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, there are currently no consensus recommendations available. The key recommendations from the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) Consensus Panel 3 (CP3) focus on the necessity of molecular studies for proper diagnosis and monitoring.
SEMINARS IN HEMATOLOGY
(2023)
Letter
Oncology
Bonnie W. Leung, Christopher J. Fay, Jordan T. Said, Anthony R. Sheets, Christine G. Lian, Jennifer R. Brown, Jorge J. Castillo, Shayna Sarosiek, Catherine Flynn, Nicole R. Leboeuf
LEUKEMIA & LYMPHOMA
(2023)
Editorial Material
Oncology
Myrna Candelaria, Luis Villela, Maria-Alejandra Torres-Viera, Camila Pena, Macarena Roa, Daniela Zambrano, Perla R. R. Colunga-Pedraza, Arianna Robles-Rodriguez, Fernando Perez-Jacobo, Ana Carolina Oliver, Maria Victoria Irigoin, Rosio Baena, Henry Idroboj, Sally R. Paredes, Rosa Oliday, Denisse Castro, Efeen Montano-Figueroa, Guillherme F. Perini, Julio D. Fernandez-Aguila, Luis E. Malpica, Brady E. Beltrank, Jorge J. Castillo
JOURNAL OF GERIATRIC ONCOLOGY
(2023)
Correction
Oncology
Javier Munoz, Shayna Sarosiek, Jorge J. Castillo
Review
Pharmacology & Pharmacy
Shayna Sarosiek, Jorge J. Castillo
Summary: This review discusses the importance and effectiveness of current and emerging targeted therapies in the treatment of Waldenstrom macroglobulinemia (WM), highlighting the significant role of Bruton tyrosine kinase inhibitors. However, the specific adverse events and the indefinite duration of therapy should be carefully considered. Additionally, other novel targeted agents of interest are also introduced.
Correction
Oncology
Javier Munoz, Shayna Sarosiek, Jorge J. Castillo